3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Neoplasms
7
Lung Neoplasms
6
Colorectal Neoplasms
5
Prostatic Neoplasms
3
Smoking Cessation
2
Neoplasm Metastasis
2
Lymphoma
2
Colonic Neoplasms
2
Breast Neoplasms
2
Uveal Melanoma
1
Stomach Neoplasms
1
Solitary Pulmonary Nodule
1
Retroviridae Infections
1
Pulmonary Disease, Chronic Obstructive
1
Pancreatic cancer, adult
1
Ovarian Neoplasms
1
Neuroblastoma
1
Neoplasm, Residual
1
Multiple Myeloma
1
Motor Activity
1
Leukemia
1
Inflammation
1
Glioblastoma
1
Esophageal Neoplasms
1
Dyspnea
1
Disease
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Cardiovascular Diseases
1
Cardiotoxicity
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
243
Carboplatin
211
Pemetrexed
177
Cisplatin
131
Paclitaxel
113
Nivolumab
101
Docetaxel
87
osimertinib
85
durvalumab
78
Specimen Handling
56
atezolizumab
55
Gemcitabine
52
Drug Therapy
52
Magnetic Resonance Spectroscopy
50
Radiosurgery
48
Radiotherapy
47
Ipilimumab
41
130-nm albumin-bound paclitaxel
39
cemiplimab
38
Bevacizumab
34
Cetuximab
30
tislelizumab
29
amivantamab
22
Taxes
22
Platinum Compounds
20
Blood Specimen Collection
20
Immunotherapy
18
Immune Checkpoint Inhibitors
18
Radiation
17
Erlotinib Hydrochloride
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Hematologic Tests
×
1 year
×
Clear all
NCT06717295
2026-01-02
CCANED-CIPHER
Dysplasia Diagnostics Limited
Recruiting
6,000 enrolled